查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1553413

造血系統惡性市場規模、佔有率、趨勢分析報告：依疾病、治療、最終用途、地區、細分市場預測，2024-2030年

Hematologic Malignancies Market Size, Share & Trends Analysis Report By Disease (Leukemia, Lymphoma), By Therapy (Chemotherapy, Immunotherapy), By End Use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

造血系統惡性市場成長與趨勢：

預計2030年全球造血系統惡性市場規模將達1,138.9億美元，預計2024年至2030年複合年成長率為8.0%。

造血系統惡性盛行率的增加和強大產品平臺的存在預計將推動市場發展。此外，併購的增加預計也將加速成長。

此外，新興國家政府正在增加醫療保健支出並發展醫療基礎設施。這可能會減少患者的自付費用，並被認為是推動造血系統惡性市場的關鍵因素之一。

最近，已證實政府消息人士正在舉措資助研究機構進行突破性的腫瘤學研究。這是市場的主要成長動力，因為它可以幫助研究機構在不受財務限制的情況下進行更大規模的研究。聯邦對腫瘤學研究的資助導致癌症檢測、預防、診斷、治療和患者生活品質方面取得了重大進展。癌症研究的進步使更多的癌症患者得到成功治療。癌症研究投資的增加預計將在預測期內推動市場成長。

造血系統惡性市場報告亮點

  • 由於強大的重磅產品管道，多發性骨髓瘤預計將成為預測期內成長最快的細分市場之一。
  • 由於可用產品數量眾多且患者人數眾多，慢性骨髓性白血病被認定為 2016 年最大的白血病亞型。
  • 由於化療作為一線治療的偏好和廣泛的產品組合，其在 2016 年的治療方法基礎上佔據了最大的市場佔有率。
  • 免疫療法因其低副作用和高效率而成為發展最快的領域。
  • 由於主要企業的本地化和併購的增加，北美在 2016 年佔據了市場主導地位。
  • 由於經濟狀況改善和醫療保健支出增加，預計亞太地區將成為未來十年成長最快的地區，2017 年至 2025 年複合年成長率良好。
  • 主要參與者包括輝瑞、羅氏、賽諾菲、百時美施貴寶、艾伯維、諾華、GlaxoSmithKline Plc、新基、強生服務，例子包括工業公司。
  • 許多主要企業都專注於擴大產品系列、開發新治療方法和進行收購。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章造血系統惡性市場的變數、趨勢和範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 造血系統惡性市場分析工具
    • 波特的分析
    • PESTEL分析

第4章造血系統惡性市場：依疾病分類的預估及趨勢分析

  • 細分儀表板
  • 造血系統惡性市場：2023 年及 2030 年疾病特異性變異分析
  • 白血病
  • 淋巴瘤
  • 骨髓瘤

第5章造血系統惡性市場：依治療方法估算與趨勢分析

  • 細分儀表板
  • 造血系統惡性市場：2023 年和 2030 年治療的變異分析
  • 化療
  • 免疫療法
  • 標靶治療
  • 其他治療

第6章造血系統惡性市場：依最終用途分類的估算與趨勢分析

  • 細分儀表板
  • 造血系統惡性市場：2023 年和 2030 年最終用途的變化分析
  • 醫院藥房
  • 零售藥房
  • 其他

第7章造血系統惡性市場：區域估計及趨勢分析

  • 2023 年及 2030 年造血系統惡性市場佔有率（按地區）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Pfizer Inc.
    • F. Hoffmann-LA Roche Ltd
    • Sanofi SA
    • Bristol-Myers Squibb Company
    • AbbVie Inc.
    • Novartis AG
    • GlaxoSmithKline PLC
    • Amgen Inc.
    • Takeda Pharmaceutical Co. Ltd
    • Johnson &Johnson
簡介目錄
Product Code: GVR-1-68038-687-5

Hematologic Malignancies Market Growth & Trends:

The global hematologic malignancies market size is estimated to reach USD 113.89 billion in 2030 and is projected to grow at a CAGR of 8.0% from 2024 to 2030. Increasing incidence of hematologic malignancies and presence of a strong product pipeline are estimated to boost the market. Moreover, increasing number of mergers and acquisitions are also expected to accelerate growth.

Furthermore, governments of developing countries are spending more on healthcare and on improving healthcare infrastructure. This is likely to reduce out-of-pocket expenditure for patients. which is considered as one of the major factors driving the hematologic malignancies market.

Recently it has been seen that the government sources are taking an initiative in funding the institutes for breakthrough oncology research. This is a major growth driver for the market as it will support the institutes to conduct their research on a larger-scale without any financial constraints. Federal government funding for research in oncology has led to a substantial development in cancer detection, prevention, diagnosis, treatment and quality of life for patients. Due to the advancement in cancer research, more patients with cancer are being successfully treated. The increasing investment in cancer research is expected to boost the growth of market during forecast period

Hematologic Malignancies Market Report Highlights:

  • Multiple myeloma is expected to be one of the fastest growing segments over the forecast period owing to strong pipeline of blockbuster products
  • Chronic myeloid leukemia was identified as the largest leukemia subtype in 2016 due to availability of large number of products and high number of target population
  • Chemotherapy held the largest share in 2016 on the basis of therapy due to its preference as first line of therapy and wide product range
  • Immunotherapy is anticipated to be the fastest growing segment and this can be attributed to lower adverse effects and higher efficiency
  • North America dominated the market in 2016 owing to local presence of key players and increasing number of mergers and acquisitions
  • Asia Pacific is expected to be the fastest growing region over the next decade with lucrative CAGR from 2017 to 2025 due to improving economic conditions and rising healthcare expenditure
  • Some of the key players are Pfizer, Inc.; F. Hoffmann-LA Roche Ltd; Sanofi; Bristol-Myers Squibb Company; AbbVie, Inc.; Novartis AG; GlaxoSmithKline PLC; Celgene Corporation; Johnson & Johnson Services, Inc.; and Takeda Pharmaceutical Company Limited
  • Most of the key players are focusing on expanding their product portfolios, development of new treatment, and acquisitions.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Hematologic Malignancies Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Hematologic Malignancies Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Hematologic Malignancies Market: Disease Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Hematologic Malignancies Market: Disease Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Leukemia
    • 4.3.1. Leukemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Lymphoma
    • 4.4.1. Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Myeloma
    • 4.5.1. Myeloma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Hematologic Malignancies Market: Therapy Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Hematologic Malignancies Market: Therapy Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Chemotherapy
    • 5.3.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Immunotherapy
    • 5.4.1. Immunotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Targeted Therapy
    • 5.5.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Other Therapies
    • 5.6.1. Other Therapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Hematologic Malignancies Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Hematologic Malignancies Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Other
    • 6.5.1. Other Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Hematologic Malignancies Market: Regional Estimates & Trend Analysis

  • 7.1. Hematologic Malignancies Market Share, By Region, 2023 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. U.K.
      • 7.3.2.1. U.K. Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Pfizer Inc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. F. Hoffmann-LA Roche Ltd
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Sanofi SA
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Bristol-Myers Squibb Company
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. AbbVie Inc.
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Novartis AG
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. GlaxoSmithKline PLC
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Amgen Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Takeda Pharmaceutical Co. Ltd
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Johnson & Johnson
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives